Pyrrolidine and azetidine compounds as ccr5 antagonists
申请人:Yang Hanbiao
公开号:US20060058284A1
公开(公告)日:2006-03-16
The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
Pyrrolidine and azetidine compounds as CCR5 antagonists
申请人:SmithKline Beecham Corporation
公开号:US07271172B2
公开(公告)日:2007-09-18
The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:EP1569933A1
公开(公告)日:2005-09-07
US7271172B2
申请人:——
公开号:US7271172B2
公开(公告)日:2007-09-18
[EN] PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES DE PYRROLIDINE ET D'AZETIDINE SERVANT D'ANTAGONISTES DE CCR5
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2004055016A1
公开(公告)日:2004-07-01
The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).